MapLight Therapeutics CEO Sells $2M Shares

MapLight Therapeutics CAO, Jonathan Gillis, sold nearly seventy thousand shares, totaling $2.09 million, in open-market trades on April 27-28, 2026. This was part of a pre-set trading plan for routine cash management. The biotech firm, focusing on brain disorder treatments, is burning cash with a net loss of $161 million over the past year. Despite this, analysts are optimistic, with a $35 target price, and the stock is up nearly 80% year-over-year, driven by anticipation of phase two data for their lead drug, ML-zero zero seven C-MA. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/32d0e2b981b8ff52